Analysts Offer Insights on Healthcare Companies: Resmed (RMD), Waters (WAT) and Teva Pharmaceutical (TEVA)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Resmed (RMD – Research Report), Waters (WAT – Research Report) and Teva Pharmaceutical (TEVA – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Resmed (RMD)
In a report released today, Brett Fishbin from KeyBanc maintained a Buy rating on Resmed, with a price target of $302.00. The company’s shares closed last Thursday at $257.61, close to its 52-week high of $263.05.
According to TipRanks.com, Fishbin is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Resmed with a $296.44 average price target, implying a 15.3% upside from current levels. In a report released today, TipRanks – xAI also upgraded the stock to Buy with a $287.00 price target.
See today’s best-performing stocks on TipRanks >>
Waters (WAT)
In a report released yesterday, Subbu Nambi from Guggenheim maintained a Buy rating on Waters, with a price target of $440.00. The company’s shares closed last Thursday at $375.18.
According to TipRanks.com, Nambi is a 5-star analyst with an average return of
Currently, the analyst consensus on Waters is a Moderate Buy with an average price target of $423.80, a 10.9% upside from current levels. In a report issued on January 27, HSBC also initiated coverage with a Buy rating on the stock with a $460.00 price target.
Teva Pharmaceutical (TEVA)
In a report released yesterday, Glen Santangelo from Barclays maintained a Buy rating on Teva Pharmaceutical, with a price target of $38.00. The company’s shares closed last Thursday at $33.07.
According to TipRanks.com, Santangelo is a 4-star analyst with an average return of
Currently, the analyst consensus on Teva Pharmaceutical is a Strong Buy with an average price target of $38.00, a 14.3% upside from current levels. In a report issued on January 16, Bank of America Securities also maintained a Buy rating on the stock with a $36.00 price target.
